ATXN1L
ATXN1L (Ataxin-1-like) is a protein that switches other genes on and off. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Pancreatic ductal adenocarcinoma and Melanoma.
Overview
Chromatin-binding factor that repress Notch signalling in the absence of Notch intracellular domain by acting as a CBF1 corepressor. Binds to the HEY promoter and might assist, along with NCOR2, RBPJ-mediated repression. Can suppress ATXN1 cytotoxicity in spinocerebellar ataxia type 1 (SCA1).
CIViC holds 2 clinical evidence items and 0 assertions across 1 variant, naming Vemurafenib, Trametinib and Dabrafenib.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · ATXN1L (Ataxin-1-like) is a protein that switches other genes on and off. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Pancreatic ductal adenocarcinoma and Melanoma.
- 1 · What it is
ATXN1L (Ataxin-1-like) is a protein that switches other genes on and off. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Pancreatic ductal adenocarcinoma and Melanoma.
- 2 · What goes wrong in cancer
Chromatin-binding factor that repress Notch signalling in the absence of Notch intracellular domain by acting as a CBF1 corepressor. Binds to the HEY promoter and might assist, along with NCOR2, RBPJ-mediated repression.
- 3 · How drugs use it
No product in this corpus aims at ATXN1L yet. Transcription factors have no pocket to plug, so drugs either degrade them or block the partner protein they need to dock on DNA.
External identifiers
Sources: HGNC HGNC:33279 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P0C7T5 (protein name, function text, keywords and locations (REST API)); CIViC gene ATXN1L (2 evidence items, 0 assertions, 1 variants; diseases: Melanoma, Pancreatic Cancer (GraphQL API, CC0))
Biology
Chromatin-binding factor that repress Notch signalling in the absence of Notch intracellular domain by acting as a CBF1 corepressor. Binds to the HEY promoter and might assist, along with NCOR2, RBPJ-mediated repression. Can suppress ATXN1 cytotoxicity in spinocerebellar ataxia type 1 (SCA1). In concert with CIC and ATXN1, involved in brain development. Location: Nucleus; Cell projection, dendrite (UniProt). Locus 16q22.2 (HGNC).
- Pancreatic ductal adenocarcinoma: CIViC evidence names this disease
- Melanoma: CIViC evidence names this disease
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC lists 3 therapies; CIViC holds 2 clinical evidence items on its variants. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"ATXN1L" OR ABSTRACT:"ATXN1L" OR TITLE:"ataxin 1 like" OR ABSTRACT:"ataxin 1 like" OR TITLE:"Ataxin-1-like" OR ABSTRACT:"Ataxin-1-like" OR TITLE:"BOAT1" OR ABSTRACT:"BOAT1") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about ATXN1L, not a curated reading list.